Oncology

Explora's senior management has decades of industry experience in cancer drug development. Our scientists routinely conduct xenograft studies for industry as well as academic scientists.  We also maintain rigorous cell culture procedures to ensure consistency in the quality of our cell lines.

Explora’s research team has:

  • Sound knowledge of tumor biology
  • Extensive experience in oncology drug development
  • Excellent technical and surgical capability
  • Established IACUC protocols

We can assist with:

  • Model selection and study design
  • In vivo drug screening
  • Mechanistic studies
  • General technical reports (GTR) generation for IND filing
  • On-site technical support and training
add articles  Design of interiors of apartments scripts PHP  project of apartments

Oncology Models:

Explora has experience with many oncology animal models used to test anti-cancer therapies, including the following:

  • Subcutaneous xenograft models (usually human tumors or cell lines transplanted into immuno-compromised rodents).
    • NCI-60 cancer cell lines (over 30 lines characterized in-house for tumorigenicity)
    • Commercial or client-produced cell lines
  • Orthotopic tumor models, which are cells implanted directly into organs of interest.
    • Mammary fat pat (mfp) model
    • Renal capsule, spleen models
    • Prostate, ovarian models
    • Brain tumor model
  • Metastatic models, which are used for testing drugs that block metastases.
    • Forced metastatic models
    • Spontaneous metastatic models
  • Hu-SCID models, which are used with human immune system substitution in development of antibody therapy and immunotherapy.
    • Human PBL grafts
    • Human immune organ grafts
    • Cord blood grafts
  • Syngeneic models, which are rodent tumors transplanted into hosts of the same genetic background to study immunotherapy and biological pathways.
    • Melanoma B16
    • Lewis lung carcinoma

Assays and Endpoints:

Explora can help you obtain high-quality, meaningful data from every study. Common assays and endpoints in oncology studies include:

  • Tumor size reduction and remission
  • Tumor growth delay
  • Decrease in metastases
  • Drug effects on host and tumor
  • Increase in lifespan of the host
  • Changes in biomarkers

Contact us to find out how Explora can help you design meaningful experiments, contain costs, meet timelines, and achieve your preclinical research goals.